Sutro Biopharma (STRO) Price & Analysis

Compare

688 Followers

STRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.52 - $4.80

Previous CloseN/A

Volume326.60K

Average Volume (3M)469.10K

Market Cap

$72.66M

Enterprise Value$74.93M

Total Cash (Recent Filing)$205.13M

Total Debt (Recent Filing)$19.59M

Price to Earnings (P/E)―

Beta3.87

Next Earnings

Nov 05, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding84,774,180

10 Day Avg. Volume399,171

30 Day Avg. Volume469,098

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue0.72

Enterprise Value/Gross Profit0.74

Enterprise Value/Ebitda-0.45

Forecast

1Y Price Target

$1.95

Price Target Upside105.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentSutro remains on track to initiate the first-in-human study for STRO-004 and STRO-006, with preclinical data suggesting improvements over existing ADCs by Pfizer/Seagen.

PartnershipsThe partnership with Astellas remains ongoing with one program entering IND-enabling toxicology, triggering a $7.5 million milestone payment.

Preclinical DataSutro Biopharma presented positive preclinical data for STRO-004, showing potent antitumor activity in several cancer models and a wider therapeutic window compared to first-generation TF ADCs.

Bears Say

Capital RequirementsThe company may need additional capital in 2026 to ensure it reaches Phase 1 data with enough cash.

Collaboration TerminationIpsen terminated the STRO-003 collaboration following a review of data and the ROR1 landscape.

Market PerformanceShares are down 58% year-to-date as the company's pivot to its earlier stage assets removes the prospect of any near-term data catalysts.

Sutro Biopharma News

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

Wells Fargo lowered the firm’s price target on Sutro Biopharma (STRO) to $3 from $4 and keeps an...

23d ago

STRO

Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers

Sutro Biopharma (($STRO)) announced an update on their ongoing clinical study. Sutro Biopharma’s recent clinical study update focuses...

14d ago

STRO

Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Hold rating on Sutro Biopharma. The associated price...

27d ago

STRO

Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results

Sutro Biopharma ( ($STRO) ) has released its Q2 earnings. Here is a breakdown of the information Sutro...

27d ago

STRO

Sutro Biopharma enters research collaboration with FDA for ADC standards

Sutro Biopharma (STRO) entered into a collaboration with the U.S. Food and Drug Administration to develop reference materials...

1M ago

STRO

Sutro Biopharma Faces NASDAQ Non-Compliance Notice

Sutro Biopharma ( ($STRO) ) has provided an announcement. On June 20, 2025, Sutro Biopharma received a notice...

2M ago

STRO

Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($STRO) ), ( ($SRPT) ), ( ($INCY) ), ( ($SIG)...

2M ago

SIG

WIX

Piper upgrades Sutro Biopharma to Overweight on attractive valuation

Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of...

3M ago

STRO

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. Published...

3M ago

STRO

Sutro Biopharma Adopts Key Proposals at Annual Meeting

Sutro Biopharma ( ($STRO) ) just unveiled an announcement. On June 6, 2025, Sutro Biopharma held its 2025...

3M ago

STRO

Sutro Biopharma appoints Greg Chow as CFO

Sutro Biopharma (STRO) announced the appointment of Greg Chow as CFO, effective June 2, 2025. Chow most recently...

3M ago

STRO

Sutro Biopharma price target lowered to 80c from $1 at BofA

BofA lowered the firm’s price target on Sutro Biopharma (STRO) to 80c from $1 and keeps an Underperform...

4M ago

STRO

Sutro Biopharma Reports Q1 2025 Earnings and Restructuring

Sutro Biopharma ( ($STRO) ) has released its Q1 earnings. Here is a breakdown of the information Sutro...

4M ago

STRO

Sutro Biopharma: Hold Rating Amid Strategic Transition and Preclinical Focus

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Hold rating on Sutro Biopharma (STRO – Research Report) today...

4M ago

STRO

STRO FAQ

What was Sutro Biopharma’s price range in the past 12 months?

Sutro Biopharma lowest stock price was $0.52 and its highest was $4.80 in the past 12 months.

What is Sutro Biopharma’s market cap?

Sutro Biopharma’s market cap is $72.66M.

When is Sutro Biopharma’s upcoming earnings report date?

Sutro Biopharma’s upcoming earnings report date is Nov 05, 2025 which is in 62 days.

How were Sutro Biopharma’s earnings last quarter?

Sutro Biopharma released its earnings results on Aug 07, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.382 by $0.242.

Is Sutro Biopharma overvalued?

According to Wall Street analysts Sutro Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sutro Biopharma pay dividends?

Sutro Biopharma does not currently pay dividends.

What is Sutro Biopharma’s EPS estimate?

Sutro Biopharma’s EPS estimate is -0.42.

How many shares outstanding does Sutro Biopharma have?

Sutro Biopharma has 84,774,180 shares outstanding.

What happened to Sutro Biopharma’s price movement after its last earnings report?

Sutro Biopharma reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.382. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sutro Biopharma?

Currently, no hedge funds are holding shares in STRO

Sutro Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-347.64%

Trailing 12-Months

Asset Growth

-46.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sutro Biopharma

Sutro Biopharma, Inc. is a biotechnology company focused on the development and commercialization of therapeutics for cancer and other serious diseases. Utilizing its proprietary cell-free protein synthesis platform, Sutro Biopharma designs and produces next-generation protein therapeutics such as antibody-drug conjugates (ADCs) and bispecific antibodies. The company's innovative approach allows for the rapid development of complex biologics, targeting various therapeutic areas, particularly in oncology.

Sutro Biopharma (STRO) Earnings & Revenues

Historic Earnings Reports

STRO Stock 12 Month Forecast

Average Price Target

$1.95

▲(105.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.9784615384615385,1.146923076923077,1.3153846153846156,1.4838461538461538,1.6523076923076925,1.820769230769231,1.9892307692307694,2.157692307692308,2.3261538461538462,2.4946153846153845,2.663076923076923,2.831538461538462,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.8976923076923078,0.9853846153846154,1.073076923076923,1.1607692307692308,1.2484615384615385,1.336153846153846,1.4238461538461538,1.5115384615384615,1.5992307692307692,1.686923076923077,1.7746153846153845,1.8623076923076922,{"y":1.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.81,0.8092307692307693,0.8084615384615386,0.8076923076923077,0.806923076923077,0.8061538461538462,0.8053846153846155,0.8046153846153846,0.8038461538461539,0.8030769230769231,0.8023076923076924,0.8015384615384615,0.8007692307692308,{"y":0.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >